Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Quantum Laboratories
mi
from
Pompano Beach, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Quantum Laboratories
mi
from
Pompano Beach, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Premiere Research Institute at Palm Beach Neurology
mi
from
West Palm Beach, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Premiere Research Institute at Palm Beach Neurology
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Fort Wayne Neurological Center
mi
from
Fort Wayne, IN
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Neurological Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Princeton Medical Institute
mi
from
Princeton, NJ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Princeton Medical Institute
mi
from
Princeton, NJ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Summit Research Network
mi
from
Portland, OR
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Summit Research Network
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Center for Cognitive Health
mi
from
Portland, OR
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Center for Cognitive Health
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Abington Neurological Associates
mi
from
Abington, PA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Abington Neurological Associates
mi
from
Abington, PA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Northeastern Pennsylvania Memory and Alzheimer's Center
mi
from
Plains, PA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Northeastern Pennsylvania Memory and Alzheimer's Center
mi
from
Plains, PA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
FutureSearch Trials
mi
from
Dallas, TX
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
FutureSearch Trials
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
National Clinical Research - Richmond, Inc.
mi
from
Richmond, VA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
National Clinical Research - Richmond, Inc.
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Banner Sun Health Research Institute
mi
from
Sun City, AZ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Arizona Health Sciences Center
mi
from
Tucson, AZ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
MCB Clinical Research Centers
mi
from
Colorado Springs, CO
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
MCB Clinical Research Centers
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Compass Research LLC
mi
from
Orlando, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Alexian Brothers Medical Center
mi
from
Elk Grove Village, IL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Alexian Brothers Medical Center
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
The Cognitive and Research Center of NJ
mi
from
Springfield, NJ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
The Cognitive and Research Center of NJ
mi
from
Springfield, NJ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Baylor AT&T Memory Center
mi
from
Dallas, TX
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Baylor AT&T Memory Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Parexel Early Phase Unit at Glendale
mi
from
Glendale, CA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Parexel Early Phase Unit at Glendale
mi
from
Glendale, CA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Care Access Research
mi
from
Santa Clarita, CA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Care Access Research
mi
from
Santa Clarita, CA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Care Access Research LLC
mi
from
Valencia, CA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Care Access Research LLC
mi
from
Valencia, CA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Medical Center
mi
from
Miami Beach, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Miami Jewish Health Systems
mi
from
Miami, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Miami Jewish Health Systems
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pensacola Research Consultants, Inc.
mi
from
Pensacola, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pensacola Research Consultants, Inc.
mi
from
Pensacola, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Roskamp Institute
mi
from
Sarasota, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Roskamp Institute
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Christie Clinic
mi
from
Champaign, IL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Christie Clinic
mi
from
Champaign, IL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Central DuPage Hospital
mi
from
Winfield, IL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Central DuPage Hospital
mi
from
Winfield, IL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Josephson Wallack Munshower Neurology P.C
mi
from
Indianapolis, IN
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Josephson Wallack Munshower Neurology P.C
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Baptist Health Medical Group
mi
from
Lexington, KY
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Baptist Health Medical Group
mi
from
Lexington, KY
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Maine Neurology
mi
from
Scarborough, ME
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Maine Neurology
mi
from
Scarborough, ME
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
ActivMed Practices & Research
mi
from
Methuen, MA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
ActivMed Practices & Research
mi
from
Methuen, MA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Donald S. Marks, M.D., P.C.
mi
from
Plymouth, MA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Donald S. Marks, M.D., P.C.
mi
from
Plymouth, MA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
ST. Luke's Hospital
mi
from
Kansas City, MO
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
ST. Luke's Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Healthy Perspectives Innovative Mental Health Services, PL
mi
from
Nashua, NH
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Healthy Perspectives Innovative Mental Health Services, PL
mi
from
Nashua, NH
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
ActivMed Practices & Research, Inc.
mi
from
Portsmouth, NH
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
ActivMed Practices & Research, Inc.
mi
from
Portsmouth, NH
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Metrolina Neurological Research Institute
mi
from
Indian Land, SC
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Metrolina Neurological Research Institute
mi
from
Indian Land, SC
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Sentara Medical Group
mi
from
Norfolk, VA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Sentara Medical Group
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Evergreen Professional Plaza
mi
from
Kirkland, WA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Evergreen Professional Plaza
mi
from
Kirkland, WA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Dean Foundation For Health Research & Education
mi
from
Middleton, WI
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Dean Foundation For Health Research & Education
mi
from
Middleton, WI
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
mi
from
Gatineau,
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
mi
from
Gatineau,
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Center for Neurosciences
mi
from
Tucson, AZ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Center for Neurosciences
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Brain Matters Research
mi
from
Delray Beach, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Brain Matters Research
mi
from
Delray Beach, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pyramid Clinical Research
mi
from
Monroe, NJ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pyramid Clinical Research
mi
from
Monroe, NJ
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Xenoscience Inc.
mi
from
Phoenix, AZ
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Xenoscience Inc.
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
NEA Baptist Clinical
mi
from
Jonesboro, AR
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
NEA Baptist Clinical
mi
from
Jonesboro, AR
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
California Research Foundation
mi
from
San Diego, CA
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
California Research Foundation
mi
from
San Diego, CA
Click here to add this to my saved trials